Physician profile
George E Blanco
NPI 1821203167
$4,541.76
in general payments reported to CMS, 2019-2025
29 companies · $885 in 2025
The $885 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $441 · 2021: $903 · 2022: $545 · 2023: $556 · 2024: $556 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $439.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $395.96 | 2019-2022 | |
| Boston Scientific Corporation | $385.21 | 2021-2024 | Watchman Access System |
| Medtronic, INC. | $382.27 | 2022-2023 | Micra, Cobalt Dr Mri Surescan, Resolute Onyx |
| Amgen INC. | $378.88 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $355.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $290.74 | 2019-2023 | Farxiga |
| Pfizer INC. | $287.28 | 2019-2025 | |
| Cvrx, INC. | $262.78 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $247.77 | 2020-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $185.97 | 2019-2025 | Camzyos |
| Abbott Laboratories | $172.28 | 2020-2023 | Cardiomems |
| Abiomed | $156.63 | 2022-2024 | Impella |
| Portola Pharmaceuticals, LLC | $81.09 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $76.43 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.64 | 2021-2022 | |
| Amarin Pharma, INC. | $50.60 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $48.38 | 2022-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.77 | 2022-2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $34.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $29.40 | 2019 | |
| Cleerly, INC. | $29.08 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Esperion Therapeutics, INC. | $28.20 | 2020-2024 | Nexletol |
| Acumed LLC | $24.67 | 2025 | Ribloc, Biobridge |
| Corcept Therapeutics | $23.40 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $22.81 | 2022 | |
| Impulse Dynamics (USA) INC. | $22.52 | 2024 | Optimizer |
| Inspire Medical Systems, INC. | $20.45 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.